- Home
- FCO vs TVRD Comparison
FCO vs TVRD Comparison
Compare FCO & TVRD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | FCO | TVRD |
|---|---|---|
| Founded | 1991 | 2017 |
| Country | United Kingdom | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 39.4M | 37.3M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | FCO | TVRD |
|---|---|---|
| Price | $3.10 | $3.94 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $51.67 |
| AVG Volume (30 Days) | ★ 100.1K | 83.6K |
| Earning Date | 01-01-0001 | 02-21-2026 |
| Dividend Yield | ★ 14.96% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.43 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $12.30 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $4.73 | $3.74 |
| 52 Week High | $6.63 | $43.65 |
Technical Indicators
Market Signals| Indicator | FCO | TVRD |
|---|---|---|
| Relative Strength Index (RSI) | 57.92 | 36.25 |
| Support Level | $3.11 | $3.84 |
| Resistance Level | $3.26 | $4.07 |
| Average True Range (ATR) | 0.09 | 0.26 |
| MACD | 0.00 | -0.04 |
| Stochastic Oscillator | 50.91 | 8.18 |
Price Performance
Historical ComparisonAbout FCO abrdn Global Income Fund Inc.
abrdn Global Income Fund Inc is a closed-end, non-diversified management investment company. The Fund's principal investment objective is to provide high current income by investing predominantly in fixed-income securities. As a secondary investment objective, the Fund seeks capital appreciation, but only when consistent with its principal investment objective. It invests in Government Bonds & Corporate Bonds, and its investments are divided into three categories, Developed Markets, Investment Grade Developing Markets and Sub-Investment Grade Developing Markets.
About TVRD Tvardi Therapeutics Inc.
Tvardi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development of novel, oral small molecule therapies targeting STAT3 to treat fibrosis-driven diseases. Its key product candidate, TTI-101, is in Phase 2 clinical development for the treatment of idiopathic pulmonary fibrosis (IPF), and hepatocellular carcinoma (HCC). Its second product candidate, TTI-109, is structurally related to, yet chemically distinct from, TTI-101 and is designed to enhance the ability to target STAT3.